FDA and social media: The regulated community's current obsession overlooks off-label promotions by the advocacy community
This morning I received a tweet exhorting me to learn about Low Dose Naltrexone (LDN) for autoimmune diseases. (Naltrexone, by the way, is approved by the FDA only to treat alcoholism.) Within a few clicks, I found claims that LDN would be a good drug to take for dozens of conditions: everything from neuroblastoma to HIV to celiac disease, and learned of a network of tweeps promoting LDN.
The above tweet linked to a blog promoting LDN which is part of the Health Central community.
All this got me thinking about a bunch of issues; ....
Continue reading this post here